Hormonal
Dietary supplementation with Docosahexaenoic acid (DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing Betacellulin (BTC) expression, thereby inhibiting the BTC-EGFR-ERBB pathway, reducing hepatic stellate cell proliferation, and lowering TGFβ-2-mediated collagen production.
If you are managing NASH or liver health, the specific type of Omega-3 matters. Research indicates DHA is more effective than EPA at suppressing key liver damage pathways (like Betacellulin and TGFβ-2). While this study is in mice, it suggests prioritizing DHA-rich sources or supplements over generic Omega-3 blends for liver-specific benefits.
Strikingly, these pathogenic processes were attenuated by DHA and to a much lesser degree by EPA... Together, our results suggest that inhibition of BTC by DHA is a key mechanism behind its beneficial effects on liver health... Strikingly, TGFB2 was the only gene found in common across several enriched categories... expression of TGFB2, but not TGFB1 was increased by BTC in vitro... repressed by DHA in both prevention and treatment mouse studies
Why this rating
Evidence is derived from preclinical mouse models (Ldlr -/-) and in vitro cell lines (LX2), not human clinical trials.
Source
Multi-omic network analysis identified betacellulin as a novel target of omega-3 fatty acid attenuation of western diet-induced nonalcoholic steatohepatitis
Jyothi Padiadpu et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2022
DOI 10.1101/2022.10.03.510635
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →